Recornea is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the cornea. The company is based in Italy. Up to 2023, the company has been focused on the pre-clinical activities related to the development of minimally invasive GROSSO® Implant, the first-ever nitinol corneal implant to restore the physiological curvature of the cornea with clear and predictable clinical outcomes in patients with keratoconus, a progressive eye disease causing distorted vision. The company is now approaching the first clinical trial for the GROSSO® Implant. The company is working to expand the core nitinol platform technology behind the GROSSO Implant to new therapeutic solutions in the pipeline for treating diseases of the eye and beyond in line with Recornea’s vision.